Entity

Time filter

Source Type

Brentwood, TN, United States

Bosserman L.D.,Wilshire Oncology Medical Group Us Oncology | Rajurkar S.P.,Wilshire Oncology Medical Group Us Oncology | Rogers K.,Nashville Oncology Associates | Chernick M.,Lankenau Institute of Medicine | And 3 more authors.
Cancer | Year: 2012

BACKGROUND: An observational prospective nonblinded clinical trial was performed to determine the effect of a drug-induced apoptosis assay results on treatments planned by oncologists. METHODS: Purified cancer cells from patient biopsies were placed into the MiCK (Microculture Kinetic) assay, a short-Term culture, which determined the effects of single drugs or combinations of drugs on tumor cell apoptosis. An oncologist received the assay results before finalizing the treatment plan. Use of the MiCK assay was evaluated and correlated with patient outcomes. RESULTS: Forty-four patients with successful MiCK assays from breast cancer (n = 16), nonsmall cell lung cancer (n = 6), non-Hodgkin lymphoma (n = 4), and others were evaluated. Four patients received adjuvant chemotherapy after MiCK, and 40 received palliative chemotherapy with a median line of therapy of 2. Oncologists used the MiCK assay to determine chemotherapy (users) in 28 (64%) and did not (nonusers) in 16 patients (36%). In users receiving palliative chemotherapy, complete plus partial response rate was 44%, compared with 6.7% in nonusers (P <.02). The median overall survival was 10.1 months in users versus 4.1 months in nonusers (P =.02). Relapse-free interval was 8.6 months in users versus 4.0 months in nonusers (P <.01). CONCLUSIONS: MiCK assay results are frequently used by oncologists. Outcomes appear to be statistically superior when oncologists use chemotherapy based on MiCK assay results compared with when they do not use the assay results. When available to oncologists, MiCK assay results help to determine patient treatment plans. © 2012 American Cancer Society.


Trademark
DiaTech Oncology | Date: 2016-05-19

Drug testing kits comprised of medical diagnostic reagents and assays for testing specimens; medical diagnostic reagents and assays for testing of body specimens; medical diagnostic reagents and assays for testing of cytotoxic, targeted biologic and immunotherapeutic treatments to determine the most effective oncological treatments. Medical testing for diagnostic or treatment purposes in the field of oncology and testing drug effectiveness; medical testing for diagnostic or treatment purposes; medical diagnostic testing, monitoring and reporting services.


Patent
DiaTech Oncology | Date: 2010-03-31

The disclosure provides a method of evaluating the ability of an anti-cancer drug candidate to induce apoptosis in a known cancer cell line by placing a single-cell suspension of a known cancer cell line in a well of a plate, adding at least one drug candidate to the well in an amount sufficient to achieve a target drug candidate concentration, measuring the optical density at selected time intervals for a selected duration of time, determining a kinetic units value from the optical density and time measurements, and correlating the kinetic units value with an ability of the anti-cancer drug candidate to induce apoptosis in the cancer cell line if the kinetic units value is positive. A similar method may be used to evaluate the ability of an anti-cancer drug candidate to induce apoptosis in a cancer type.


A computer system is provided for determining the relative effectiveness of anti-cancer drugs. The interface has selectable options, including an option to manage drug testing parameters, and enables user selection of desired drug testing parameters in relation to a virtual well plate associated with a physical well plate of a spectrophotometer. The computer system causes the spectrophotometer to start a drug test, wherein the physical well plate includes at least one test well containing viable cancer cells; and at least one drug candidate in a predetermined concentration; and at least one control well containing the viable cancer cells alone. The system records the optical density of the well at a predetermined wavelength at selected time intervals for a selected duration of time, and stores the optical density and time measurements in the database. An activity value is calculated from the optical density and time measurements, and a correlation is displayed between the activity value and the drug candidates ability to induce apoptosis in the cancer cells.


Trademark
DiaTech Oncology | Date: 2011-07-28

Pharmaceutical preparations for the treatment of cancer; Drug testing kits comprised of medical diagnostic reagents and assays for testing specimens; Medical diagnostic reagents and assays for testing of body specimens; Medical diagnostic reagents and assays for testing of apoptosis concentrations to determine the most effective oncological treatments. Medical services; Medical testing for diagnostic or treatment purposes in the field of oncology and testing drug effectiveness; Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring and reporting services.

Discover hidden collaborations